These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27537059)

  • 1. Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.
    Agabiti SS; Liang Y; Wiemer AJ
    Mol Membr Biol; 2016 Mar; 33(1-2):1-11. PubMed ID: 27537059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.
    Haney SL; Wills VS; Wiemer DF; Holstein SA
    Molecules; 2017 May; 22(6):. PubMed ID: 28555000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
    Wiemer AJ; Yu JS; Lamb KM; Hohl RJ; Wiemer DF
    Bioorg Med Chem; 2008 Jan; 16(1):390-9. PubMed ID: 17905588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation.
    Agabiti SS; Li J; Wiemer AJ
    Cell Death Dis; 2017 Mar; 8(3):e2678. PubMed ID: 28300835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target.
    Muehlebach ME; Holstein SA
    Clin Transl Med; 2023 Jan; 13(1):e1167. PubMed ID: 36650113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geranylgeranyl diphosphate synthase: an emerging therapeutic target.
    Wiemer AJ; Wiemer DF; Hohl RJ
    Clin Pharmacol Ther; 2011 Dec; 90(6):804-12. PubMed ID: 22048229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Key Enzymes for the Mevalonate Pathway in the Cardiovascular System.
    Zhang C; Jin DD; Wang XY; Lou L; Yang J
    J Cardiovasc Pharmacol; 2021 Feb; 77(2):142-152. PubMed ID: 33538531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.
    Wasko BM; Dudakovic A; Hohl RJ
    J Pharmacol Exp Ther; 2011 May; 337(2):540-6. PubMed ID: 21335425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.
    Zhao Y; Wu TY; Zhao MF; Li CJ
    J Biol Chem; 2020 Apr; 295(15):5152-5162. PubMed ID: 32139507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy.
    Pham AC; Holstein SA; Borgstahl GEO
    Mol Cancer Ther; 2024 Jan; 23(1):14-23. PubMed ID: 37756579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of a series of aromatic bisphosphonates.
    Barney RJ; Wasko BM; Dudakovic A; Hohl RJ; Wiemer DF
    Bioorg Med Chem; 2010 Oct; 18(20):7212-20. PubMed ID: 20832326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
    Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes.
    Dudakovic A; Wiemer AJ; Lamb KM; Vonnahme LA; Dietz SE; Hohl RJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1028-36. PubMed ID: 18083912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS.
    Henneman L; van Cruchten AG; Kulik W; Waterham HR
    Biochim Biophys Acta; 2011 Apr; 1811(4):227-33. PubMed ID: 21237288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors.
    Reilly JE; Zhou X; Tong H; Kuder CH; Wiemer DF; Hohl RJ
    Biochem Pharmacol; 2015 Jul; 96(2):83-92. PubMed ID: 25952057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amides as bioisosteres of triazole-based geranylgeranyl diphosphate synthase inhibitors.
    Goetz DB; Varney ML; Wiemer DF; Holstein SA
    Bioorg Med Chem; 2020 Aug; 28(16):115604. PubMed ID: 32690260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of α-modifications on the activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
    Fairweather AER; Goetz DB; Schroeder CM; Bhuiyan NH; Varney ML; Wiemer DF; Holstein SA
    Bioorg Med Chem; 2021 Aug; 44():116307. PubMed ID: 34298413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase.
    Allen C; Kortagere S; Tong H; Matthiesen RA; Metzger JI; Wiemer DF; Holstein SA
    Mol Pharmacol; 2017 Mar; 91(3):229-236. PubMed ID: 28057800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
    Matthiesen RA; Varney ML; Xu PC; Rier AS; Wiemer DF; Holstein SA
    Bioorg Med Chem; 2018 Jan; 26(2):376-385. PubMed ID: 29248353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers.
    Waller DD; Park J; Tsantrizos YS
    Crit Rev Biochem Mol Biol; 2019 Feb; 54(1):41-60. PubMed ID: 30773935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.